Altogether, the above results suggest that PFD@Gel treatment can remodel the TPME of ccRCC by reducing ECM deposition and blocking the TGF‐β1 signaling pathway, thus lowering tumor stiffness to increase vascular perfusion and alleviate hypoxia for favorable drug delivery and immune cell infiltration. This evidence concerns the gene TGFB1 and neoplasm.